Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

OptiBiotix rejig will allow the life sciences group pay a dividend

Rather than making regular cash pay-outs, the company wants to be able to sanction a “dividend in specie” that would allow it to distribute its holding in SkinBioTherapeutics
word 'dividends' marked on file
The company is seeking shareholder approval for the changes

Life sciences group OptiBiotix Health plc (LON:OPTI) is seeking shareholder consent to re-organise its capital structure so it can make future dividend payments.

Rather than making regular cash pay-outs, the company wants to be able to sanction a “dividend in specie” that would allow it to distribute its holding in SkinBioTherapeutics PLC (LON:SBX).

READ: Coffee that loses you weight among products being developed by Optibiotix

After spinning off the business, which is focused on treatments that use and modify the microbiome that resides on the skin, OptiBiotix still holds 41.9% of the separately listed firm.

The mechanics

The nuts and bolts of what is essentially a procedural matter are as follows: a proposed capital reduction will lead to the cancellation of OptiBiotix’s share premium account.

This will then create distributable reserves that will allow it to pay dividends either in cash, or in specie “should circumstances in the future make it desirable to do so”.

WATCH: Massive opportunities for OptiBiotix Health's new and improved SlimBiome

Distributing shares in SkinBioTherapeutics means OptiBiotix is not forced to sell stock in the market and then make a cash return.  

Greater flexibility 

“The ability to make dividend payments provides the flexibility to consider paying a 'dividend in specie' to the company's shareholders of shares it holds in SkinBioTherapeutics, should it be appropriate to do so,” said Opti’s chief executive Stephen O'Hara.

“This is part of our strategy of building value across OptiBiotix divisions and where possible releasing value back to shareholders."

The company is a specialist in the emerging area of life science that involves the gut microbiome and is developing functional foods and treatments that help lower cholesterol, aid weight loss and which could help prevent diabetes.

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

numerous pills
March 23 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use